Phase i clinical trial of lenalidomide in combination with temsirolimus in patients with advanced cancer

Investigational New Drugs

Volumn 31, Issue 6, 2013, Pages 1505-1513

  Ganesan, Prasanth ^a   Piha Paul, Sarina ^a   Naing, Aung ^a   Falchook, Gerald ^a   Wheler, Jennifer ^a   Janku, Filip ^a   Zinner, Ralph ^a   Laday, Shell ^a   Kies, Merrill ^a   Tsimberidou, Apostolia M ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

Advanced cancer; Lenalidomide; Phase I trial; Temsirolimus

Indexed keywords

BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; LENALIDOMIDE; OXALIPLATIN; SORAFENIB; TEMSIROLIMUS;

ADENOID CYSTIC CARCINOMA; ADRENAL CORTEX CARCINOMA; ADULT; ADVANCED CANCER; ANEMIA; ANOREXIA; ANTICOAGULANT THERAPY; ARTICLE; BLOOD TOXICITY; CANCER PATIENT; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG DOSE ESCALATION; DRUG RESPONSE; DRUG TOLERABILITY; ENDOMETRIUM CARCINOMA; FATIGUE; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEADACHE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPERTRIGLYCERIDEMIA; INFECTION; KIDNEY FAILURE; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; MERKEL CELL TUMOR; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PAROTID GLAND CARCINOMA; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RASH; SARCOMA; SOFT TISSUE SARCOMA; STUDY DESIGN; THROMBOCYTOPENIA; THROMBOSIS; VERY ELDERLY; VOMITING; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIROLIMUS; THALIDOMIDE; TOR SERINE-THREONINE KINASES; YOUNG ADULT;

EID: 84888643141     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-013-0013-1     Document Type: Article

References (28)

1. Dredge K, Horsfall R, Robinson SP, Zhang LH, Lu L, Tang Y, Shirley MA, Muller G, Schafer P, Stirling D, Dalgleish AG, Bartlett JB (2005) Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro. Microvasc Res 69(1-2):56-63. doi: 10.1016/j.mvr.2005.01.002
2. Corral LG, Haslett PA, Muller GW, Chen R, Wong LM, Ocampo CJ, Patterson RT, Stirling DI, Kaplan G (1999) Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 163(1):380-386
3. Schafer PH, Gandhi AK, Loveland MA, Chen RS, Man HW, Schnetkamp PP, Wolbring G, Govinda S, Corral LG, Payvandi F, Muller GW, Stirling DI (2003) Enhancement of cytokine production and AP-1 transcriptional activity in T cells by thalidomide-related immunomodulatory drugs. J Pharmacol Exp Ther 305(3):1222-1232. doi: 10.1124/jpet.102.048496
4. Segler A, Tsimberidou AM (2012) Lenalidomide in solid tumors. Cancer Chemother Pharmacol 69(6):1393-1406. doi: 10.1007/s00280-012-1874-2
5. Petrylak D, Resto-Garces K, Tibyan M, Mohile S (215) A phase I open-label study using lenalidomide and docetaxel in castration- resistant prostate cancer. J Clin Oncol 7s: psuppl; abstr 5156
6. Papadopoulos K, Mendelson D, Preston G (2005) A phase I study of lenalidomide and weekly docetaxel in patients with advanced solid tumors. Clin Cancer Res 11(24 Pt 2):215, Abstracts of the International Conference on Molecular Targets and Cancer Therapeutics
7. Simpson D, Curran MP (2008) Temsirolimus: in advanced renal cell carcinoma. Drugs 68(5):631-638
8. Hidalgo M, Rowinsky EK (2000) The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19(56):6680-6686. doi: 10.1038/sj.onc.1204091
9. Raje N, Kumar S, Hideshima T, Ishitsuka K, Chauhan D, Mitsiades C, Podar K, Le Gouill S, Richardson P, Munshi NC, Stirling DI, Antin JH, Anderson KC (2004) Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104(13):4188-4193. doi: 10.1182/blood-2004- 06-2281
10. Hofmeister CC, Yang X, Pichiorri F, Chen P, Rozewski DM, Johnson AJ, Lee S, Liu Z, Garr CL, Hade EM, Ji J, Schaaf LJ, Benson DM Jr, Kraut EH, Hicks WJ, Chan KK, Chen CS, Farag SS, Grever MR, Byrd JC, Phelps MA (2011) Phase I trial of lenalidomide and CCI-779 in patients with relapsed multiple myeloma: evidence for lenalidomide-CCI-779 interaction via P-glycoprotein. J Clin Oncol 29(25):3427-3434. doi: 10.1200/JCO.2010.32.4962
11. Smith SM CK, Kline JP, Zavala JD, Conner K, Thomas SP, Lesho P, Doyle LA, Stadler WM, Karrison T, Kimball AS (2012) Phase I trial of temsirolimus and lenalidomide in pts with rel/ref lymphomas. J Clin Oncol 2012 ASCO Annual Meeting Proceedings (Post-Meeting Edition) 30 (suppl):1
12. Tsimberidou AM, Iskander NG, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, Luthra R, Ye Y, Wen S, Berry D, Kurzrock R (2012) Personalized medicine in a phase I clinical trials program: the MD Anderson Cancer Center initiative. Clin Cancer Res 18(22):6373-6383. doi: 10.1158/1078-0432.CCR-12-1627
13. Institute NC (2006) Common Terminology Criteria for Adverse Events v3.0 (CTCAE). National Cancer Institute. http://ctep.cancer.gov/protocolDevelopment/ electronic-applications/docs/ctcaev3.pdf. Accessed 18 Dec 2012
14. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92(3):205-216
15. Ratain MJ, Eisen T, Stadler WM, Flaherty KT, Kaye SB, Rosner GL, Gore M, Desai AA, Patnaik A, Xiong HQ, Rowinsky E, Abbruzzese JL, Xia C, Simantov R, Schwartz B, O'Dwyer PJ (2006) Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol 24(16):2505-2512. doi: 10.1200/JCO.2005.03.6723
16. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, Park Y, Liou SH, Marshall B, Boni JP, Dukart G, Sherman ML (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22(5):909-918. doi: 10.1200/JCO.2004.08.185
17. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356(22):2271-2281. doi: 10.1056/NEJMoa066838
18. Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne KJ, Dalgleish AG (2006) Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 42(14):2318-2325. doi: 10.1016/j.ejca.2006.05. 018
19. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, Leister C, Korth-Bradley J, Hanauske A, Armand JP (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22(12):2336-2347. doi: 10.1200/JCO.2004.08.116
20. Smith SM, Cohen KS, Kline JP, Zavala JD, Conner K, Thomas SP, Lesho P, Doyle LA, Stadler WM, Karrison T (2012) Phase I trial of temsirolimus and lenalidomide in pts with rel/ref lymphomas. J Clin Oncol 30 (suppl; abstr 8075)
21. Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J (2010) Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 116(1):146-154. doi: 10.1002/cncr.24686
22. Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY (2009) Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer 115(22):5228-5236. doi: 10.1002/cncr.24576
23. Amato RJ, Hernandez-McClain J, Saxena S, Khan M (2008) Lenalidomide therapy for metastatic renal cell carcinoma. Am J Clin Oncol 31(3):244-249. doi: 10.1097/COC.0b013e31815e451f
24. Choueiri TK, Dreicer R, Rini BI, Elson P, Garcia JA, Thakkar SG, Baz RC, Mekhail TM, Jinks HA, Bukowski RM (2006) Phase II study of lenalidomide in patients with metastatic renal cell carcinoma. Cancer 107(11):2609-2616. doi: 10.1002/cncr.22290
25. Chawla SP, Blay J, Ray-Coquard IL, Le Cesne A, Staddon AP, Milhem M, Penel N, Riedel RF (2011) Results of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT). J Clin Oncol 29 (suppl; abstr 10005)
26. Chawla SP, Staddon AP, Baker LH, Schuetze SM, Tolcher AW, D'Amato GZ, Blay JY, Mita MM, Sankhala KK, Berk L, Rivera VM, Clackson T, Loewy JW, Haluska FG, Demetri GD (2012) Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol 30(1):78-84. doi: 10.1200/JCO.2011.35.6329
27. Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Oberg K (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364(6):514-523. doi: 10.1056/NEJMoa1009290
28. Janku F, Tsimberidou AM, Garrido-Laguna I, Wang X, Luthra R, Hong DS, Naing A, Falchook GS, Moroney JW, Piha-Paul SA, Wheler JJ, Moulder SL, Fu S, Kurzrock R (2011) PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors. Mol Cancer Ther 10(3):558-565. doi: 10.1158/1535-7163.MCT-10-0994